Sam Alworth is the chief executive officer of AcuraStem Inc., a biotechnology start-up working to transform outcomes for patients with neurodegenerative disease. AcuraStem's predictive iNeuroRx™ platform has identified a novel ALS target and preclinical lead candidate. This work was heralded in the February 5, 2018 issue of Nature Medicine for its groundbreaking research.
Alworth has over 15 years’ experience in life science entrepreneurship, product management, R&D and business development; securing over $18M in private investment and non-dilutive government R&D funding. Alworth has the bioinformatics and machine learning expertise required to create innovative experiments using human cell models. He holds several U.S. patents and has contributed to multiple peer-reviewed scientific journals. Sam is fluent in Chinese, has a global perspective, and a deep passion for using technolog